The company's Curian immunoassay instrument is currently in front of the FDA, and the PediaStat will likely be submitted later this year.
The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.
Diagnostics segment revenues for the company fell 5 percent to $38.4 million, and life sciences revenues dropped 15 percent to $12.6 million.
The company's Lyo-Ready 1-Step RT-qPCR mix is being used by diagnostic labs in China to develop screening assays for the virus.
Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.
The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.
The company's platform and assay use fluorescent lateral flow technology to detect Helicobacter pylori antigens in human stool samples.
Of the 27 companies in the index, 14 firms' stocks were down, while 13 companies' share prices increased.
The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.
Within the company's diagnostics segment, revenues for molecular assays in particular declined 21 percent year over year.
